HCM News & Events

Hutchmed announced that the new drug application, or NDA, for Orpathys has been granted conditional approval by the China National Medical Products Administration, or NMPA, for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments.

Innovent Biologics and Hutchmed jointly announce that the new drug application for the combination of Tyvyt and Elunate has been granted approval by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy and have not received programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy in the first-line setting.